Albireo Pharma IncのEBITDA
Albireo Pharma IncのEBITDAは何ですか。
Albireo Pharma IncのEBITDAは-112.20$です。
EBITDAの定義は何ですか。
EBITDA は、会社の営業成績を表す利息、税金、減価償却費および償却費を控除する前の利益です。
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
NASDAQのセクタHealth CareにおけるEBITDAの企業と比べるAlbireo Pharma Inc
Albireo Pharma Incは何をしますか。
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Albireo Pharma Incと類似のebitda
- Jianzhong Construction DevelopmentのEBITDAは-113.30¥です。
- Kadmon IncのEBITDAは-113.20$です。
- GeronのEBITDAは-113.06$です。
- Pliant TherapeuticsのEBITDAは-112.61$です。
- Avalara IncのEBITDAは-112.60$です。
- Christine InternationalのEBITDAは-112.46¥です。
- Albireo Pharma IncのEBITDAは-112.20$です。
- KadmonのEBITDAは-112.01$です。
- InhibrxのEBITDAは-111.79$です。
- Apollo Future MobilityのEBITDAは-111.73HKD$です。
- Ballard Power SystemsのEBITDAは-111.66$です。
- Housing Development and InfrastructureのEBITDAは-111.53₨です。
- ALX OncologyのEBITDAは-111.40$です。